Tag Archives: Dewey Steadman

Canaccord Genuity Keeps Their Buy Rating on SCYNEXIS (SCYX)

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on SCYNEXIS (NASDAQ: SCYX) today and set a price target of $4. The company’s shares opened today at $1.41. Steadman commented: “We’d use any weakness in SCYX shares to build long

KemPharm (KMPH) Gets a Buy Rating from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on KemPharm (NASDAQ: KMPH) today and set a price target of $11. The company’s shares opened today at $4.80. According to TipRanks.com, Steadman is a 3-star analyst with an average return

Canaccord Genuity Maintains Their Hold Rating on Endo International (ENDP)

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Endo International (NASDAQ: ENDP), with a price target of $13. The company’s shares opened today at $15.09. Steadman said: “We view Athenex’s compounded vasopressin launch

Canaccord Genuity Sticks to Its Hold Rating for Lipocine (LPCN)

In a report released yesterday, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Lipocine (NASDAQ: LPCN), with a price target of $1.50. The company’s shares opened today at $1.50, close to its 52-week low of $1.03. According to

Canaccord Genuity Remains a Buy on Aerie Pharma (AERI)

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Aerie Pharma (NASDAQ: AERI) yesterday and set a price target of $86. The company’s shares opened today at $63.80. Steadman said: “We hosted Aerie CFO a fireside chat this afternoon

Canaccord Genuity Sticks to Its Buy Rating for ProMetic Life (PLI)

ProMetic Life (TSX: PLI), the Healthcare company, has received a rating update from a Wall Street analyst today. Analyst Dewey Steadman from Canaccord Genuity rated ProMetic Life (TSX: PLI) a Buy, setting a C$2 price target. Steadman commented: “We think